NCT02518139 - A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

1,060

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

June 30, 2017

Study Completion Date

June 30, 2017

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

TD-4208

Subjects receiving TD-4208 are blinded to one of two doses of 4208.

DRUG

Tiotropium

There is not a placebo, there is an active comparator (Tiotropium) arm.

Trial Locations (1)

Palmetto Medical Research Associates L.L.C, Easley